Q-omics provides the consensus-scored WNT3A profile across patient tissues and cancer cell-line models. WNT3A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, WNT3A is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, WNT3A RNA expression shows 11,155 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight CESC, LUAD, and ESCA as cancer lineages where WNT3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WNT3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WNT3A survival associations across molecular data types. WNT3A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WNT3A RNA expression–survival associations across cancer types. High WNT3A expression shows unfavorable associations in THCA, ACC and COAD, but favorable associations in CESC, SCLC and LUAD. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for WNT3A RNA expression.
This table summarizes WNT3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for WNT3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WNT3A shows lower tumor expression in LUAD, KIRC, LUSC and KICH and higher tumor expression in HNSC and COAD. The LUAD box plot shows higher WNT3A RNA expression in normal versus tumor tissue (log2 FC = −3.565, t-test p < 0.001).
This table shows molecular features associated with WNT3A in patient tissues and cancer cell lines. In patient samples, WNT3A shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, WNT3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
